Shots:

• Blueprint will receive $25M up front, ~$590M in milestones along with royalties on net sales of BLU-945 & BLU-701 in Greater China & will retain all rights to BLU-945 & BLU-701 globally
• Zai Lab will get the rights to develop & exclusively commercialize BLU-945 & BLU-701 in  Greater China & will lead the development costs for both products
• The collaboration combines Blueprint's precision therapy expertise with Zai Lab's development capabilities to accelerate the global development of BLU-945 & BLU-701 for NSCLC. Additionally, BLU-945 is currently being evaluated in the P-I/II SYMPHONY trial for EGFR-driven NSCLC & P-I/II trial of BLU-701 is expected to initiate in Q4'21

  Ref: PR Newswire | Image: Blueprint